November, 2021 - Instylan

SAFETY AND EFFICACY OF INTRAVESICAL ADMINISTRATION FOR SYMPTOM CONTROL IN CHRONIC CYSTOPATHY

Posted on 04.11.202105.05.2023 by admin

INTRODUCTION: Chronic cystopathy is a widespread pathology. Intravesical hyaluronic acid (instillation) is one of the treatment options for cystopathies. This study analyzed safety and efficacy of intravesical hyaluronic acid instillations in patients with symptoms of urinary blabber disease.

Continue reading “SAFETY AND EFFICACY OF INTRAVESICAL ADMINISTRATION FOR SYMPTOM CONTROL IN CHRONIC CYSTOPATHY” →

Intravesical instillation of high molecular weight sodium hyaluronate in radiation‑induced cystitis: a prospective pilot study

Posted on 03.11.202105.05.2023 by admin

Purpose. To assess the efficacy and safety of intravesical instillation of high molecular weight sodium hyaluronate (HMW- HA) for the treatment of radiation-induced cystitis.

Continue reading “Intravesical instillation of high molecular weight sodium hyaluronate in radiation‑induced cystitis: a prospective pilot study” →

SELF-MEDICATION CAN BE HARMFUL TO YOUR HEALTH

Before using the product offered on this information resource, it is recommended to consult your doctor and read the instructions.

Information about medical products for the professional work of health professionals. INSTYLAN (INSTILAN) 0.16% colorless, transparent, viscous gel of hyaluronic acid of non-animal origin, sterile, physiological pH.

INSTYLAN 0,16% approved as Class ІІa medical devices. EU Declaration of Conformity. Registration number: DD 60107286 0001 Manufacturer: Diaco Biofarmaceutici S.R.L. Via Flavia 124, 34147, Trieste, Italy. E-mail: info@diaco.it. www.diaco.it.

Search

Month: November 2021

SAFETY AND EFFICACY OF INTRAVESICAL ADMINISTRATION FOR SYMPTOM CONTROL IN CHRONIC CYSTOPATHY

Intravesical instillation of high molecular weight sodium hyaluronate in radiation‑induced cystitis: a prospective pilot study

Search

[:en]Subscribe2[:it]Subscribe2[:es]Subscribe2[:ua]Subscribe2[:fr]Subscribe2[:]